Pelthos Therapeutics Inc. – Material Contracts Watch

from 8-K 16 pages Pelthos Therapeutics Inc. 2026 Equity Incentive Plan

from 10-Q 9 pages Pelthos Therapeutics Inc. 2023 Equity Incentive Plan Performance Stock Unit Agreement

from 8-K 12 pages Separation and Release Agreement

from 10-Q 2 pages First Amendment to Executive Employment Agreement

from 10-Q 2 pages First Amendment to Executive Employment Agreement

from 8-K 10 pages Executive Employment Agreement

from 8-K 3 pages Down Payment Agreement for Xeglyze Assets Purchase

from 8-K 17 pages Asset Purchase Agreement

from 8-K 46 pages Certain Confidential Information Contained in This Exhibit Have Been Omitted by Means of Redacting a Portion of the Text and Replacing It With [***], Pursuant to Regulation S-K Item 601(b)(10) of the Securities Act of 1933, as Amended. Certain Confidential Information Has Been Excluded From This Exhibit Because It Is: (I) Not Material; and (II) the Registrant Treats Such Information as Private or Confidential. License and Api Supply Agreement

from 8-K 42 pages Certain Confidential Information Contained in This Exhibit Have Been Omitted by Means of Redacting a Portion of the Text and Replacing It With [***], Pursuant to Regulation S-K Item 601(b)(10) of the Securities Act of 1933, as Amended. Certain Confidential Information Has Been Excluded From This Exhibit Because It Is: (I) Not Material; and (II) the Registrant Treats Such Information as Private or Confidential

from 8-K 3 pages Amendment No. 1 to Assignment Agreement

from 8-K 6 pages Amendment No. 1 to Purchase and Sale Agreement

from 8-K 5 pages Form of Amended and Restated Lock-Up Agreement

from 8-K 42 pages Registration Rights Agreement

from 8-K 12 pages Pledge Agreement

from 8-K 62 pages Securities Purchase Agreement

from 8-K/A 25 pages Exclusive License and Sublicense Agreement

from 8-K/A 30 pages Master Services Agreement for Product Supply

from 8-K/A 22 pages Assignment Agreement

from 8-K/A 29 pages Contract Manufacturing Agreement This Contract Manufacturing Agreement (The “Agreement”) Made and Executed as of This 12th Day of February, 2025 (Hereinafter Referred to as “Date of Agreement”) by and Between Lnhc, Inc., a Company Organized Under the Laws of the State of Delaware in the United States of America, With Its Principal Offices at 4020 Stirrup Creek Drive, Suite 110, Durham, Nc 27703 U.S.A. (Hereinafter “Company”), and Orion Corporation, a Company Organised Under the Laws of Finland, (Business Identity Code Fi 19992126), With Its Principal Offices at Orionintie 1, 02200 Espoo, Finland (Hereinafter Referred to as “Orion”). Each of Company and Orion Referred to Herein After as a “Party” and Collectively as the “Parties”